title: Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth.
abstract: Androgen receptor (AR) is a ligand-activated transcription factor that requires androgen binding to initiate a series of molecular events leading to specific gene activation. AR has been suggested to form an antiparallel homodimer based on the characteristics of high affinity interaction between the amino (N) and carboxyl (C) termini of it. Recently, it is suggested that AR N-to-C interaction is critical for the ability of this receptor to up-regulate the transcription of androgen-responsive genes, and may be a new target for treatment of prostate cancer (PCa). In this study, we investigated the effect of N-terminal (1-34) peptide of AR (ARN34) on androgen-dependent function in PCa cell. Ectopic expression of ARN34 suppressed both androgen-dependent AR N-to-C interaction and prostate specific antigen transcription. Ectopic expression of ARN34 also caused delaying translocation to the nucleus and the decreasing stability of the AR. Stable expression of ARN34 suppressed androgen-dependent cell growth of LNCaP cells. Moreover, transactivation and cell growth of the AR variant in LNCaP cells by the AR antagonist, hydroxyflutamide, were also inhibited by ARN34. Although treatment of LNCaP cells with androgen drove transition of cells from G1 to S-phase, the cells expressing ARN34 were inhibited to enter into S phase in the presence of androgen. This cell cycle arrest was attended by decrease in cyclin E levels and cyclin-dependent-kinase 2 activity, and increase in p27 levels. Our results demonstrated that disruption of AR N-to-C interaction caused by ARN34 leads to AR dysfunction and inhibition of AR-mediated prostate cancer cell growth. This approach is thus considered to provide a useful therapeutic opinion for blocking AR-mediated PCa growth.
authors.affiliation: Institute for Chemotherapy, Microbial Chemistry Research Foundation, Numazu, Shizuoka, Japan. k-minamiguchi@taiho.co.jp
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Minamiguchi
authors.forename: Manabu
authors.initials: M
authors.lastname: Kawada
authors.forename: Shun-Ichi
authors.initials: S
authors.lastname: Ohba
authors.forename: Kozo
authors.initials: K
authors.lastname: Takamoto
authors.forename: Masaaki
authors.initials: M
authors.lastname: Ishizuka
mesh_terms: D021581:Active Transport, Cell Nucleus / Q000187:drug effects; D001483:Base Sequence; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D004347:Drug Interactions; D005485:Flutamide / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D007399:Interphase / Q000187:drug effects; D008297:Male; D010446:Peptide Fragments / Q000235:genetics / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000473:pathology*; D011944:Receptors, Androgen / Q000737:chemistry / Q000378:metabolism / Q000502:physiology*; D015533:Transcriptional Activation / Q000187:drug effects; D014162:Transfection
chemical_list: D010446:Peptide Fragments; D011944:Receptors, Androgen; C014290:hydroxyflutamide; D005485:Flutamide